Americana Partners’s Lucid Diagnostics LUCD Stock Holding History

Americana Partners’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.3K	Hold	26,427	–	–	﹤0.01%	596
2026 Q1	$30.4K	Hold	26,427	–	–	﹤0.01%	510
2025 Q4	$28.8K	Hold	26,427	–	–	﹤0.01%	474
2025 Q3	$26.7K	Hold	26,427	–	–	﹤0.01%	455
2025 Q2	$30.4K	Hold	26,427	–	–	﹤0.01%	419
2025 Q1	$39.4K	Hold	26,427	–	–	﹤0.01%	371
2024 Q4	$21.6K	Buy	+26,427	New	+$23.3K	﹤0.01%	384

Other funds holding LUCD

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Americana Partners's LUCD Position: Q2 2026 in Review

Americana Partners held its Lucid Diagnostics (LUCD) position steady in Q2 2026 at 26,427 shares worth $28.3K. The position accounts for ﹤0.01% of the portfolio, ranked #596.

Americana Partners first reported a position in LUCD in Q4 2024 and has held it in 7 quarters since. The position peaked at $39.4K in Q1 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

Americana Partners held 26,427 shares of Lucid Diagnostics worth $28.3K as of Q2 2026.
Americana Partners left its Lucid Diagnostics share count unchanged in Q2 2026.
Lucid Diagnostics made up ﹤0.01% of Americana Partners's portfolio in Q2 2026, its #596 holding.
Americana Partners first reported a position in Lucid Diagnostics in Q4 2024 and has held it in 7 quarters since.
Americana Partners's Lucid Diagnostics position peaked at $39.4K in Q1 2025.
116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Americana Partners's 13F filing for Q2 2026, filed 5 Aug 2026.